METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION
First Claim
1. An antibody composition useful for radioimmunotherapy comprising an agonistic 4-1BB recombinant antibody, a radionuclide marker molecule and a conjugated toxin.
2 Assignments
0 Petitions
Accused Products
Abstract
The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
7 Citations
20 Claims
- 1. An antibody composition useful for radioimmunotherapy comprising an agonistic 4-1BB recombinant antibody, a radionuclide marker molecule and a conjugated toxin.
-
7. (canceled)
-
13-16. -16. (canceled)
-
18. (canceled)
Specification